Gemcitabine plus oxaliplatin for patients with advanced hepatocellular carcinoma using two different schedules (Q33358104)

26 July 2017

title

Gemcitabine plus oxaliplatin for patients with advanced hepatocellular carcinoma using two different schedules (English)

1 reference

26 July 2017

1 reference

hepatocellular carcinoma

1 reference

1

Julien Taïeb

1 reference

26 July 2017

Emmanuel Boleslawski

5

0 references

Valérie Boige

object named as

Valerie Boige

12

0 references

Thierry Poynard

object named as

Thierry Poynard

11

0 references

author name string

Luminita Bonyhay

2

1 reference

26 July 2017

Lamia Golli

3

1 reference

26 July 2017

Michel Ducreux

4

1 reference

26 July 2017

Jean-Marie Tigaud

6

1 reference

26 July 2017

Thierry de Baere

7

1 reference

26 July 2017

Touraj Mansourbakht

8

1 reference

26 July 2017

Marie Anna Delgado

9

1 reference

26 July 2017

Laureut Hannoun

10

1 reference

26 July 2017

language of work or name

English

0 references

publication date

1 December 2003

1 reference

26 July 2017

number of pages

7

1 reference

inferred from page(s)

published in

Cancer

1 reference

26 July 2017

volume

98

1 reference

26 July 2017

issue

12

1 reference

26 July 2017

page(s)

2664-2670

1 reference

Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11869

Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11869

Review article: Overview of medical treatments in unresectable hepatocellular carcinoma--an impossible meta-analysis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11869

A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11869

Treatment of hepatocellular carcinoma: a systematic review of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11869

Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11869

Expression of P-glycoprotein in hepatocellular carcinoma. A determinant of chemotherapy response

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11869

Expression of P-glycoprotein and p53 in advanced hepatocellular carcinoma treated by single agent chemotherapy: clinical correlation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11869

Supraadditive effect of 2',2'-difluorodeoxycytidine (gemcitabine) in combination with oxaliplatin in human cancer cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11869

Phase II study of gemcitabine in patients with advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11869

Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: final results of a GERCOR multicenter phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11869

Phase I-II and pharmacokinetic study of gemcitabine combined with oxaliplatin in patients with advanced non-small-cell lung cancer and ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11869

Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11869

Reporting results of cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11869

Phase II trial of uracil/tegafur (UFT) plus leucovorin in patients with advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11869

A random phase II study of mitoxantrone and cisplatin in patients with hepatocellular carcinoma. An ECOG study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11869

A multi-centre randomized phase II study of nolatrexed versus doxorubicin in treatment of Chinese patients with advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11869

Phase II trial to topotecan in hepatocellular carcinoma: a Southwest Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11869

A phase II study of irinotecan in patients with advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11869

Phase II and pharmacokinetic study of paclitaxel therapy for unresectable hepatocellular carcinoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11869

Treatment of advanced hepatocellular carcinoma with biweekly high-dose gemcitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11869

Gemcitabine and doxorubicin for the treatment of patients with advanced hepatocellular carcinoma: a phase I-II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11869

The effects of impaired liver function on the elimination of antineoplastic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11869

Dosage adjustment and pharmacokinetic profile of irinotecan in cancer patients with hepatic dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11869

Epidemiology of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11869

7 January 2021

Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11869

7 January 2021

Doxorubicin for unresectable hepatocellular carcinoma. A prospective study on the addition of verapamil

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11869

7 January 2021

A phase II study of raltitrexed ('Tomudex') in patients with hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11869

7 January 2021

Pharmacokinetics of anticancer agents in patients with impaired liver function

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11869

7 January 2021

Phase I study of a weekly 1 h infusion of paclitaxel in patients with unresectable hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11869

7 January 2021

Identifiers

DOI

10.1002/CNCR.11869

1 reference

26 July 2017

1 reference